ORIC Pharmaceuticals, Inc. (ORIC)
NASDAQ: ORIC · Real-Time Price · USD
7.93
-0.22 (-2.70%)
May 18, 2026, 4:00 PM EDT - Market closed
ORIC Pharmaceuticals Employees
ORIC Pharmaceuticals had 104 employees as of March 31, 2026. The number of employees decreased by 18 or -14.75% compared to the same quarter last year.
Employees
104
Change
-18
Growth
-14.75%
Revenue / Employee
n/a
Profits / Employee
-$1,300,135
Market Cap
820.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 104 | -18 | -14.75% |
| Dec 31, 2025 | 104 | -11 | -9.57% |
| Sep 30, 2025 | 106 | -6 | -5.36% |
| Jun 30, 2025 | 128 | 21 | 19.63% |
| Mar 31, 2025 | 122 | 20 | 19.61% |
| Dec 31, 2024 | 115 | 15 | 15.00% |
| Sep 30, 2024 | 112 | 19 | 20.43% |
| Jun 30, 2024 | 107 | 18 | 20.22% |
| Mar 31, 2024 | 102 | 14 | 15.91% |
| Dec 31, 2023 | 100 | 14 | 16.28% |
| Sep 30, 2023 | 93 | 5 | 5.68% |
| Jun 30, 2023 | 89 | 6 | 7.23% |
| Mar 31, 2023 | 88 | 9 | 11.39% |
| Dec 31, 2022 | 86 | 8 | 10.26% |
| Sep 30, 2022 | 88 | 14 | 18.92% |
| Jun 30, 2022 | 83 | 13 | 18.57% |
| Mar 31, 2022 | 79 | 13 | 19.70% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Xencor | 260 |
| Kura Oncology | 260 |
| Omeros | 175 |
| Sana Biotechnology | 142 |
| Aura Biosciences | 113 |
| Annexon | 93 |
| Theravance Biopharma | 90 |
| Arbutus Biopharma | 19 |
ORIC News
- 3 days ago - Oric Pharmaceuticals moved to Buy rating at Goldman Sachs - TheFly
- 4 days ago - ORIC Pharmaceuticals Slides: Company presentation - Filings
- 13 days ago - Oric Pharmaceuticals price target lowered to $16 from $17 at Citi - TheFly
- 14 days ago - Oric Pharmaceuticals reports Q1 EPS (34c), consensus (32c) - TheFly
- 14 days ago - ORIC® Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Updates - GlobeNewsWire
- 14 days ago - ORIC Pharmaceuticals Earnings release: Q1 2026 - Filings
- 14 days ago - ORIC Pharmaceuticals Quarterly report: Q1 2026 - Filings
- 17 days ago - ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire